What is the pathophysiology of ascites?

Pathophysiology of Ascites in Cirrhosis

Ascites formation in cirrhosis requires two essential components working in tandem: portal (sinusoidal) hypertension and renal sodium/water retention, both driven by splanchnic arterial vasodilation that creates a state of effective arterial underfilling. 1

Core Pathophysiologic Mechanisms

Portal Hypertension: The Structural Foundation

Portal hypertension is absolutely required for ascites development - fluid accumulation does not occur when the portal pressure gradient remains below 8 mm Hg. 1 The mechanism involves:

• Increased intrahepatic resistance (~75% of the problem): Progressive collagen deposition and nodule formation in cirrhosis fundamentally alter the liver's vascular architecture, increasing resistance to portal blood flow. 1

• Dynamic vasoconstriction (~25% of the problem): Activated hepatic stellate cells become contractile and regulate sinusoidal tone dynamically. Reduced nitric oxide (NO) production/bioavailability in the cirrhotic liver further increases vascular tone. 1

• Increased splanchnic blood flow: Portal pressure rises further as splanchnic arterial vasodilation increases blood flow into an already high-resistance system, exacerbating portal hypertension. 1

Critical distinction: Presinusoidal portal hypertension (like isolated portal vein thrombosis) rarely causes ascites unless liver function is compromised, while postsinusoidal hypertension (like acute hepatic vein thrombosis) typically produces ascites. This confirms that sinusoidal pressure elevation is the key factor. 1

The Vasodilation-Underfilling Cascade

Splanchnic arterial vasodilation is the central initiating event that triggers the entire pathophysiologic cascade. 1

• Mechanism of vasodilation: When portal pressure rises, intestinal microvasculature generates angiogenic factors (vascular endothelial growth factor), stimulating portosystemic collateral development. Further pressure increases induce endothelial nitric oxide synthase, causing NO overproduction and profound splanchnic arterial vasodilation. 1

• Effective hypovolemia: Despite total blood volume expansion, splanchnic vasodilation creates "effective arterial underfilling" - the body perceives inadequate arterial filling despite actual hypervolemia. 1

• Systemic vasodilators: Portosystemic collaterals permit vasodilators (NO, prostacyclin, endocannabinoids) to enter systemic circulation, perpetuating the vasodilated state. 1

Renal Sodium and Water Retention

The kidneys respond to perceived arterial underfilling by activating powerful sodium-retaining systems. 1

• Sympathetic nervous system activation: Stimulates sodium reabsorption in proximal tubules, distal tubules, loop of Henle, and collecting ducts. 1

• Renin-angiotensin-aldosterone system (RAAS): Activated by effective hypovolemia, leading to aldosterone-mediated sodium absorption from distal tubules and collecting ducts. 1

• Arginine-vasopressin release: Non-osmotic release of vasopressin acts on V2 receptors in collecting ducts, impairing free water clearance and contributing to dilutional hyponatremia. 1

• Net result: Positive sodium balance leads to extracellular fluid volume expansion, with portal hypertension acting as a "compartmentalizing factor" that directs this expanded fluid volume into the peritoneal cavity. 1

Fluid Transudation into Peritoneum

Elevated sinusoidal hydrostatic pressure directly favors fluid transudation into the peritoneal cavity. 1

• Lymphatic overflow: Splanchnic arterial vasodilation increases arterial blood inflow into splanchnic microcirculation, raising capillary hydrostatic pressure and causing excessive splanchnic lymph production that exceeds lymphatic return capacity. 2

• Direct leakage: Lymph leaks from the liver surface and other splanchnic organs directly into the abdominal cavity. 2

• Sinusoidal changes: Collagen deposition in the space of Disse makes sinusoids less distensible, further increasing pressure. 1

Emerging Pathophysiologic Concepts

Systemic Inflammation

Recent evidence highlights bacterial translocation and systemic inflammation as additional contributors. 1

• Portal hypertension increases gut permeability, allowing bacterial translocation and pathogen-associated molecular patterns to activate innate immune responses. 1

• This triggers systemic inflammation with release of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), reactive oxygen species, and reactive nitrogen species. 1, 3

• Inflammation contributes to both vasodilation and organ dysfunction, creating a vicious cycle. 1, 3

Cellular Mechanisms

Multiple cell types contribute through activation and altered function. 3

• Hepatic stellate cells, sinusoidal endothelial cells, and smooth muscle cells worsen ascites through extracellular matrix deposition and paracrine signaling. 3

• Macrophages (resident and infiltrating) promote inflammation and dysregulate lymphatic reabsorption. 3

• Lymphangiogenesis becomes dysregulated, impairing the lymphatic system's ability to reabsorb peritoneal fluid. 3

Clinical Implications

Understanding this pathophysiology explains why ascites only develops when both conditions are met: sufficient portal hypertension (≥8 mm Hg gradient) AND activation of sodium-retaining mechanisms. 1 This dual requirement underlies the therapeutic approach targeting both portal pressure reduction (beta-blockers, TIPS) and sodium balance (diuretics, sodium restriction). 1

The development of ascites marks a critical turning point - 5-year survival drops from ~80% in compensated cirrhosis to ~30% once ascites develops, making this an indication for liver transplantation evaluation. 1